radioimmunotherapy (rit) of non-hodgkin’s lymphoma (nhl) is said to be more advantageous compared to unlabelled therapeutic antibodies. to this date, radiolabelled murine anti-cd20 mabs, zevalin® and bexxar® have been approved for imaging and therapy. a preparation containing rituximab, chimeric mab radioimmunoconjugate suitable for lu-177 labeling, could provide better imaging and therapeutic ...

Background: The B-cell antigen CD20 is expressed on normal B-cells and almost all lymphomas. This non-modulating agent provides an excellent target for antibody-directed therapeutic regimens. IDECC2B8 (rituximab) a monoclonal antibody (mAb) directed against the B-cell-specific CD20. mediates complement antibody-dependent cell-mediated cytotoxicity. As its usage has surged, there have been growi...

Despite the major advances in conventional forms of treatment (i.e. surgical techniques, radiotherapy and chemotherapy) and improved survival rates, cancer is still the second leading cause of death in developing countries. One major limitation of cytotoxic drugs and radiation in the treatment of cancer patients is their inability to discriminate between malignant and normal tissues. This in tu...

despite the major advances in conventional forms of treatment (i.e. surgical techniques, radiotherapy and chemotherapy) and improved survival rates, cancer is still the second leading cause of death in developing countries. one major limitation of cytotoxic drugs and radiation in the treatment of cancer patients is their inability to discriminate between malignant and normal tissues. this in tu...

background: myocardial infarction (mi) is one of the most common and serious diseases resulting from coronary artery occlusion and major reduction in blood flow. streptokinase as a thrombolytic is considered the first and most important therapeutic intervention for reperfusion following mi in most countries including iran. our previous study showed that, the prevalence of high antibody titers a...